Human Longevity, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Human Longevity, Inc.
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
Biopharma start-ups finally had an increase in financing activity, following three sequential quarters with a decrease. A review of biopharma start-up dealmaking and financing activity from January through March 2018, based on data from Strategic Transactions.
Celularity launched with $250m to develop cell therapies with technology licensed from Celgene and others, while mRNA specialist Moderna brought in another $500m mega round and Generation Bio closed a $100m Series B to fund ongoing gene therapy programs.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Gene Therapy, Cell Therapy
Drug Discovery Technologies
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.